Printer Friendly

ST. JUDE MEDICAL ANNOUNCES FDA APPROVAL OF ITS HEMODYNAMIC PLUS (HP) SERIES OF THE ST. JUDE MEDICAL MECHANICAL HEART VALVE

 ST. PAUL, Minn., Nov. 17 ~PRNewswire~ -- St. Jude Medical, Inc. , (NASDAQ-NMS: STJM) announced today it has received Food & Drug Administration (FDA) approval to distribute its new Hemodynamic Plus (HP) Series of the St. Jude Medical mechanical heart valve in the United States.
 The HP Series was developed to provide optimum hemodynamics in patients who have a small valvular annulus. The HP Series offers in excess of a 25 percent increase in valve orifice area over other mechanical heart valves. Utilizing the same design and carbon materials that have set the standard for prosthetic heart valves since l977, the valves are available in l7mm, l9mm and 2lmm sizes in both aortic and mitral configurations. With the addition of the HP Series, surgeons can now choose from a full range of St. Jude Medical mechanical heart valves for their valve replacement needs.
 Lawrence A. Lehmkuhl, president and chief executive officer, stated, "We believe the superior hemodynamice of the HP Series will make these valves the cardiovascular surgeon's first choice in treating the smaller annulus patient. The HP Series has been well received in Europe since being introduced in September."
 St. Jude Medical, Inc., a multinational manufacturer and marketer of the world's most preferred mechanical heart valve with over 425,000 implantations since 1977, serves physicians worldwide with the highest quality products for cardiovascular care.
 -0- 11~17~92
 ~CONTACT: Paul Vetter, asst. treasurer, 612-481-7773, or Steve Wilson, V.P. finance & CFO, 612-481-7542, both of St. Jude Medical~
 (STJM)


CO: St. Jude Medical, Inc. ST: Minnesota IN: MTC SU: PDT

KH -- MN008 -- 1879 11~17~92 13:05 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 17, 1992
Words:266
Previous Article:GAS PRICE DROPS .3 CENT IN ONE WEEK, AAA REPORTS
Next Article:BALLISTIVET REPORTS THIRD QUARTER RESULTS
Topics:


Related Articles
FDA APPROVES THREE MORE SIZES OF ST. JUDE MEDICAL MECHANICAL HEART VALVE HEMODYNAMIC PLUS (HP) SERIES
ST. JUDE MEDICAL ANNOUNCES FIRST EUROPEAN IMPLANTATIONS OF NEW PACESETTER PACEMAKER
ST. JUDE MEDICAL ANNOUNCES FIRST IMPLANT OF ROTATABLE MECHANICAL HEART VALVE
ST. JUDE MEDICAL, INC. ANNOUNCES THAT PACESETTER, INC. HAS RECEIVED FDA CLEARANCE TO MARKET THREE NEW PACEMAKERS IN THE U.S.
ST. JUDE MEDICAL AND HEARTPORT TO PURSUE LESS INVASIVE HEART VALVE SURGERY
ST. JUDE MEDICAL RECEIVES CE MARK APPROVAL FOR AORTIC ROTATABLE MECHANICAL HEART VALVE & ANNOUNCES MITRAL VERSION
ST. JUDE MEDICAL ANNOUNCES FIRST U.S. IMPLANTS OF ROTATABLE MECHANICAL HEART VALVE AND CE MARK APPROVAL
ST. JUDE MEDICAL ANNOUNCES EUROPEAN IMPLANTS OF HEART VALVE REPAIR PRODUCT
St. Jude Medical Expands Tissue Valve Products
St. Jude Medical Announces U.S. Commercial Release of Tissue Valve

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters